Recent U.S. policy changes and the introduction of the Inflation Reduction Act (IRA) have injected a sense of urgency within pharma companies for greater cross functional cooperation. The traditional route that drugs take through the development process from bench to patient needs a radical rethink. Any pressure on how drugs are assessed through the AA route will further ramp up the urgency within pharma to align internally.
Tag Archive for: Payers
Market access emerged as a crucial commercial function at pharmaceutical manufacturers a little over 20 years ago, followed closely by the creation of specialized market access agencies. With so much changing over the last two decades, the time is right to take a fresh look at how market access agencies support manufacturers today to ensure that expectations are aligned and that unrealized potential doesn’t negatively impact brands.
How pharma companies can communicate effectively in today’s evolving marketplace and why it is the right time to embrace our humanity when engaging various stakeholders along the product, patient, and reimbursement/coverage journeys.
Part V: Cost pressures, increasing value while improving health outcomes, and leveraging real-world evidence are top of mind.
This first-to-market technology gives patient service teams nearly immediate insight into patient coverage from both pharmacy and major medical plans, the potential need for prior authorization support, and any financial responsibilities impacting patient access and speed to treatment.
the Digital Medicine Society (DiMe) released findings from a digital health industry needs assessment to identify 1) the drivers of successful digital health product development and adoption, and 2) the regulatory policy needed to facilitate these drivers.
Although the bulk of gene therapy research is still focused on rare disease, recent launches show that certain chronic conditions could be successfully treated with this technology.
There’s no shortage of information dedicated to reconciling the rewards and risks of cell and gene therapies, and how payers and employers can best provide access to potentially transformative treatments while factoring in price and affordability. We believe that the classical game theory paradox, the “prisoner’s dilemma,” may provide useful insights in helping the various stakeholders develop solutions for how best to cover CGTs.
As oncology drugs receive accelerated approvals, payers are questioning whether the benefits of these products outweigh the cost, spurring manufacturers to explore value-based agreements.
As early as 2023, pharmaceutical manufacturers and payers will have to contend with one of the more imminent potential impacts of the law: inflationary rebates for Medicare utilization.